Option, License and Collaboration Agreement entered into in October 2023 under which the company received an $85 million upfront cash payment and Gilead holds opt-in and license rights to the company's programs.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Jason A. Okazaki
Also a director
Chief Executive Officer and President
|
50 | Not stated | Not stated | $2,482,987 | |
|
William E. Delaney IV, Ph.D.
Chief Scientific Officer
|
54 |
Since 2020
6 years
|
Not stated | $1,264,904 | |
|
Anuj Gaggar, M.D., Ph.D.
Chief Medical Officer
|
48 |
Since 2023
3 years
|
Not stated | $1,246,051 | |
|
Nicole S. White, Ph.D.
Chief Manufacturing Officer
|
46 |
Since 2022
4 years
|
2020 | Not reported | |
|
Jeanette M Bjorkquist
PFO and PAO
Title from the Form 4 dated Oct 30, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Option, License and Collaboration Agreement entered into in October 2023 under which the company received an $85 million upfront cash payment and Gilead holds opt-in and license rights to the company's programs.
Common Stock Purchase Agreement and Investor Rights Agreement entered into in October 2023 under which Gilead made an upfront equity investment by purchasing 1,089,472 shares.
Gilead participated in an August 2025 financing, purchasing 2,295,920 shares of common stock with accompanying Class A and Class B Warrants.
Loading...